Participants | Treatment | Length of Trial | Outcomes | References |
---|---|---|---|---|
50 IBS children, Rome II criteria. | Lactobacillus GG vs placebo. | 6 weeks | LGG ↓ incidence abdominal distention. | [50] |
48 IBS patients, Rome II criteria. | VSL#3 vs placebo. | 4 and 8 weeks | ↓ flatulence and colonic transit. | [39] |
30 Rome III FC patients; 30 controls. | VSL#3 vs placebo. | 2 weeks | VSL#3 ↑complete spontaneous bowel movements. | [40] |
59 IBS children. | VSL#3 vs placebo. | 6 weeks | VSL#3 ↓ abdominal pain/discomfort, and bloating/gassiness. | [33] |
104 children diagnosed with FAPD, IBS or FD. | Lactobacillus GG vs placebo. | 4Â weeks. | LGG treatment moderately improved abdominal pain. | [30] |
105 FBD patients. | sc-FOS vs placebo. | 6 weeks | sc-FOS ↓ intensity of digestive disorder symptoms ↑ quality of life, ↑ discomfort scores. | [56] |